Phase 2 - Feasibility Study of supplemental area Clinical Trial Manufacturing Facility (CTMF)

As part of the Government of Canada's policy to develop vaccine expertise in Canada, the NRC is
mandated to build a manufacturing plant for clinical batches of vaccines of different types. A
first phase was completed in 2023 and consisted of the construction of a vaccine manufacturing
facility (see attached drawings). The second phase consists of adding a viral vector ball room on
the first floor, an mNRA vaccine production suite and a Quality Control Laboratory on the
second floor of an existing building, the project includes all necessary utilities needed for the
scope of work:

 Complete the viral vector manufacturing ball room, room 157 with an area of 112 m2,
 Add a mNRA vaccine production suite using part of room 210 with an area of 278,5 m2,
 Add a Quality Control Laboratory (Chemistry and Microbiology) in room 210 if possible
or in a building extension,
 Add necessary services and utilities needed to produce the vaccines in the new
production areas,
 Production rooms and utilities required will follow the following standards:
o Health Canada Good Manufacturing Practices (GMP)
o FDA Current Good Manufacturing Practices (cGMP)
o Eudralex GMP standards